This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis. Featured content in
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) reported its financial results for its third quarter of fiscal 2023, the period
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space Clearmind
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical–stage natural psychedelic drug development company, today announced that the Company has signed a
Noted experts in cardiovascular rehabilitation attending the Third Jim Pattison-Mazankowski Alberta Heart Institute Cardiac Rehabilitation Symposium (Banff, April 21-23, 2023) observed that although cardiac rehabilitation
Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart
WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by boosting domestic pharmaceutical manufacturing. Biden announced the initiative at the
Share this article Acelyrin does not plan to utilize this CRO for any new trials evaluating izokibep, after finding that a vendor used by the
UKHSA and the Met Office have issued an amber Cold-Health Alert (CHA) in 3 regions of England. A yellow CHA has also been issued in